cerdulatinib

Cerdulatinib is an orally bioavailable small molecule dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated kinases (JAK), including JAK1 and JAK3, with potential anti-inflammatory and antineoplastic activity. It inhibits two key signaling pathways that promote cancer cell growth in certain hematologic malignancies: the B-cell receptor pathway via Syk and key cytokine receptors via JAK. Cerdulatinib is being developed primarily for the treatment of hematological malignancies such as peripheral T-cell lymphoma (PTCL), chronic lymphocytic leukemia (CLL), follicular lymphoma, marginal zone lymphoma, Waldenstrom macroglobulinemia, and diffuse large B-cell lymphoma (DLBCL). The drug has demonstrated broad anti-tumor activity in preclinical models by inducing apoptosis, blocking cell cycle progression, and inhibiting downstream signaling through the JAK/STAT pathway. Cerdulatinib was granted orphan drug status by the FDA for PTCL[1][3][4][5][6][8].

Other names

cerdulatinibcerdulatinib [INN]1198300-79-6UNII-D1LXQ45S1OUNII-D-1LXQ45S1OUNII-D 1LXQ45S1O